🇺🇸 FDA
Patent

US 11001594

Heterocyclic modulators of HIF activity for treatment of disease

granted A61KA61K31/4245A61K31/427

Quick answer

US patent 11001594 (Heterocyclic modulators of HIF activity for treatment of disease) held by The Board of Regents of the University of Texas System expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/4245, A61K31/427, A61K31/437, A61K31/4439